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CLINICAL PROFILE, CLINICOPATHOLOGICAL CORRELATION & 
OUTCOME OF ADULT MEMBRANOUS NEPHROPATHY 
ABSTRACT: 
 Background: Membranous nephropathy (MN) is one of the most common causes 
of primary glomerulopathy causing nephrotic syndrome in adults. Primary 
membranous nephropathy is the common type accounting for 75-80%. Remaining 
20% -25% can be secondary to systemic autoimmune disorders like systemic lupus 
erythematosis, chronic infections like hepatitis B and hepatitis C, malignancy and 
variety of drugs. This study is aimed at analyzing the profile of membranous 
nephropathy in South Indian population as there is limited information in this 
regard. 
Methods: In this prospective observational study, we included 98 biopsy proven 
MN patients. Five patients were excluded from the study, as they had end stage 
renal disease at the time of presentation. Remaining 93 patients were categorized 
as primary and secondary after screening for the possible causes of MN. The 
epidemiological profile of study population was analyzed. The clinical, 
biochemical and histopathological parameters among primary and secondary MN 
patients were compared. The response rate & predictors of response to 
immunosuppressive treatment evaluated. The risk factors for progression to 
chronic kidney disease were also analyzed. 
  Results: After screening for secondary causes 56/93 (60%) were diagnosed as 
primary MN and remaining 37/93 (40%) were secondary MN. The underlying 
causes of secondary MN patients were lupus nephritis (n=28), malignancy (n=3), 
hepatitis B virus (n=2) rheumatoid arthritis (n=1), and native drugs (n=3).  Most of 
our primary MN patients were within 40-60 years of age 55% (31/56) and 66% 
(37/56) of primary MN were males. Primary MN patients had severe disease at the 
time of presentation when compared to the secondary MN patients (uPCR 
4.75mg/mg vs.3.60 mg/mg, p=<0.001; serum albumin 3.07g/dl vs.3.49 g/dl 
p=<0.001; serum cholesterol 224 mg/dl vs. 184mg/dl p=<0.001).Fifty seven 
percent (21/37) of secondary MN had at least 1+ C1q staining when compared to 
7% ( 4/56) in those with primary disease.   
   Out of 56 primary MN patients, 30 % (17/56) of patients achieved   
remission. Out of 33 patients who received modified Ponticelli regimen 24 % 
(8/33) achieved remission. Spontaneous remission occurred in 9 out of these 14 
patients (64%) who were under conservative therapy. Patients who had not 
remitted had severe disease when compared to those who remitted. (uPCR 5.3 
mg/mg vs. 3.3 mg/mg p=<0.001; serum albumin 2.8 g/dl vs. 3.47 g/dl p=<0.001; 
serum cholesterol 241mg/dl vs.184mg/dl p=0.0017).            
  During the follow up of 56 primary MN patients, (median follow up period 
was 18 months), 10 % (6/56) of them developed progressive renal failure. Out of 
the 6 patients who progressed to renal failure, 67% (4/6) had interstitial fibrosis 
and tubular atrophy of >25% when compared to 6% (3/50) in those who had stable 
renal function. Five out of 6 (83%) patients progressing to renal failure had 
nephrotic proteinuria as compared to 37 out of 50 patients (74%) having stable 
renal function. Only one patient out of 6 patients who progressed to renal failure 
had remitted (16%) as compared to  16 out of 50 (32%) in stable renal function 
group.  
Conclusion:  
 Primary MN was more common than secondary MN in our study 
accounting for about 60%.  
 Primary MN was common within 40-60 years of age and males were 
commonly affected than females. 
 Primary MN had severe disease at the time of presentation.  
 C1q staining in the biopsy was more common in secondary MN 
 Patients having severe disease at the time of presentation had poor 
remission rate (both in conservative and immunosuppressive therapy) when 
compared to those with mild disease. 
 Interstitial fibrosis and tubular atrophy of >25% in the initial biopsy picture 
was a definite risk factor for progression to renal impairment. Patients with   
nephrotic proteinuria and those who did not remit had higher rate for 
progression to chronic kidney disease (not statistically significant) in our 
study.  
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INTRODUCTION: 
             Membranous nephropathy (MN) is one of the most common causes of 
primary glomerulopathy causing nephrotic syndrome in adults [1]. Primary 
membranous nephropathy is the common type accounting for 75-80%. It is now 
considered as kidney specific autoimmune disease as up to 70% of patients have 
M- type Anti phospholipase A- 2 receptor (a receptor in the podocytes) antibody in 
their serum[2,3]. Remaining 20% -25% can be secondary to systemic autoimmune 
disorders like systemic lupus erythematosis, chronic infections like hepatitis B and 
hepatitis C, malignancy and variety of drugs[2]. Usually one third of patients with 
primary MN remit spontaneously and one third has persistent proteinuria with 
stable renal function. Around 40% of   these patients reach end stage renal disease 
[46]. In addition, these patients have increased risk of morbidity and mortality due 
to thromboembolic and cardiovascular complications [7]. Patients with lesser 
degree of proteinuria are treated conservatively by angiotensin converting enzyme 
inhibitors or angiotensin II receptor blocker or in combination. Though these drugs 
reduce proteinuria, they have no effect on disease course. Moderate to high risk 
patients are treated with disease specific therapy like corticosteroids, alkylating 
agents, Cyclosporine A, and Tacrolimus [9,46]. Other drugs like 
adrenocorticotropic hormone and selective B cells depleting agents like Rituximab 
have shown promising effect in some studies. But most of the time, it is difficult to 
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decide up on therapeutic strategy. Membranous nephropathy recurs in kidney 
allograft in up to 40% of those undergo renal transplant. 
              This study is aimed at analyzing the profile of membranous nephropathy 
in South Indian population as there is limited information in this regard. 
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Aim: 
 
1. To study the epidemiological profile of adult MN patients. 
 
2. To compare the clinical, biochemical and histopathological parameters 
among primary and secondary MN patients. 
 
3. To evaluate the response rate & predictors of response to 
immunosuppressive treatment. 
 
4. To analyze risk factors for progression to chronic kidney disease.  
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EPIDEMIOLOGY 
 
                 Membranous nephropathy is one of the most common causes of primary 
glomerulonephropathy causing nephrotic syndrome in non diabetic adult 
population [1]. Incidence is about 1 in 1, 00,000 in general population. It accounts 
for 30-35% of biopsy in adult nephrotic syndrome .This increases age mounting to 
maximum of 50%. The peak incidence is in fourth to fifth decade of life. Onset of 
membranous nephropathy outside this usual range is more likely to be secondary 
MN. This is relatively uncommon in pediatric population (less than 5%). Adult to 
child ratio is 26:1.Male is commonly affected and the ratio is 2:1.Incidence and 
prevalence of MN in general population shows a considerable variation among 
geographical regions. The incidence is slightly lower in UK and is slightly higher 
in Greece and Macedonia .This variation is of unknown cause. This may be due to 
the variation in prevalence of hepatitis and malaria causing secondary MN forms.  
 
Genetics: 
          Patients with HLA- DR3 have three fold increased risk for MN. HLA B8 
and HLA B18 are also associated with MN among Caucasian population. In 
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Japanese population, MN is associated with the HLA DR 2 haplotype. Rare forms 
of familial MN have also been reported.  
 
Causes of membranous nephropathy: 
         MN is either primary (of unknown cause) or secondary to varying etiologies 
like infections, drugs, toxins, autoimmune diseases and malignancy.  Diagnostic 
work up differs significantly between the two forms. Also for secondary MN, 
therapy is focused on underlying cause but idiopathic MN is treated with 
immunosuppressant drugs. Most common type is primary MN, accounting for 
about 75%. 
Primary MN:  
        Primary MN remained as a diagnosis of exclusion till 2009, when Beck et al 
demonstrated autoantibodies against M–type PLA2R, a membrane glycoprotein 
located in the podocytes in 60%-80% of such patients. This landmark discovery 
supports the notion that idiopathic MN is an organ limited autoimmune disease 
[37,38,39,40]. 
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Secondary MN:  
                        Secondary MN may be due to systemic autoimmune disorders like 
systemic lupus nephritis, rheumatoid arthritis, chronic viral infections like hepatitis 
B and hepatitis C, malignancy, variety of drugs and alloimmunity like 
hematopoietic stem cell transplant. Secondary MN can be suspected to some extent 
by few characteristic pathological features in renal biopsy along with evidence of 
systemic features or drug intake. Correction of the systemic illness or withdrawal 
of the offending drug resulting in remission of the disease shows that the MN is of 
secondary type [23]. 
              It should be noted that cause of the MN may be primary though secondary 
causes can co-exist with it, as shown in few studies.IgG4 in renal biopsy, which is 
characteristic of primary MN was demonstrated in some MN associated with 
malignancy and hepatitis B infection.    
 
Autoimmune disorders:   
           Most common type of autoimmune disorder causing secondary MN is 
systemic lupus erythematosis. Lupus nephritis class V as per ISN/RPS 
classification accounts for 10-20% of renal involvement in systemic lupus 
erythematosis. It usually affects young females. It is indistinguishable from 
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primary MN clinically. High degree of suspicion is required as nephrotic syndrome 
predates onset of other systemic manifestations of lupus erythematosis. Also these 
patients have normal complement levels with undetectable or low ANA levels. 
Biopsy shows mesangial and or endocapillary proliferation with thickening of 
capillary basement membrane. Immunofluorescence shows varying immune and 
complement deposits to the tune of full house pattern with immunoglobulin of non 
IgG4 type. Course of the disease is similar to that of primary MN and has 
relatively good long term prognosis compared to class III or class IV lupus 
nephritis. 
       Rheumatoid arthritis as such or therapeutic drugs like gold, penicillamine, 
bucillamine (which were used previously for rheumatoid arthritis) or nonsteroidal 
anti inflammatory drugs can cause MN. Ankylosing spondylitis, autoimmune 
thyroiditis, IgG4 related disease and Sarcoidosis, Systemic sclerosis, 
Dermatomyositis, Graves’s disease, mixed connective-tissue disease and Sjögren 
syndrome are other autoimmune disorders associated with MN. Whether they are 
true causative etiologies or just coincidental is not known.  
Infections: 
          Persistent antigenemia due to long standing infections causes MN. These 
include viral infections like chronic hepatitis B infection and hepatitis C infection 
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(common is membranoproliferative pattern of glomerulonephritis and 
cryoglobulinemic glomerulonephritis) [17,28], human immunodeficiency virus, 
chronic malarial infection, enterococcal endocarditis, syphilis, leprosy, hydatid 
cyst, schistosomiasis and filariasis. This is supported by the fact that on treating 
these infections, proteinuria remits and pathogenic antigens formed from the 
parasites have been isolated from the immune complex deposits in the glomeruli. 
     Among Asian race 30-40% of infection associated MN is due to chronic 
hepatitis B viral infection. These patients show surface antigen, anti-core antibody 
and e-antigen positive in their serum with normal or mild elevation of 
transaminases. The e antigen was separated from the immune complex deposits 
confirming its pathogenic potential in causing the disease. MN related to hepatitis 
B infection and lupus nephritis class V are only two MN associated with 
hypocomplementemia. Treatment of infection with antiviral drug results in 
remission of disease. 
Malignancy: 
              Elderly MN patients have increased incidence of malignancy when 
compared to general population .It is said that MN can precede, occur with or 
succeed onset of other symptoms related to malignancy. Common malignancies 
associated with MN are solid organ tumors like lung carcinoma, gastrointestinal 
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malignancy (colon& stomach), prostatic carcinoma in males and carcinoma breast 
in females. Other rare associated malignancies include non Hodgkin’s lymphoma 
and chronic lymphocytic leukemia.  Carcinoembyonic antigen has been 
demonstrated in the immune deposits in glomeruli. So it is advisable to screen 
every elderly MN patients for occult malignancy. 
Drugs and toxins: 
     Drugs like gold, penicillamine or bucillamine which were used previously for 
Rheumatoid arthritis or nonsteroidal anti inflammatory drugs, captopril, lithium 
probenecid and mercurial compound can cause MN. Temporal profile exists 
between the drug exposure and onset of symptoms. Remission of proteinuria 
occurs in months to years after withdrawing the offending drug. 
Alloimmunity: 
          Membranous nephropathy develops when immune system is exposed to non 
self antigen chronically such as in renal transplantation and hematopoietic 
transplantation. This is supported by the fact that denovo MN developing post 
renal transplant .MN occurring  after hematopoietic stem cell transplant may be 
due to graft versus host reaction. Rare form of MN in neonates of mother having 
neutral endopeptidase deficiency is also due to alloimmunisation. 
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Evolution of concept of Pathogenesis: 
                    In 1959, the  first insight of  pathogenesis of  primary MN was 
provided  by Walter  Heymann  through  his rat models .There are two models of 
Heymann nephritis viz  one the active model and other the passive model. Active 
model was developed by immunizing rats with either emulsion of whole rat cortex 
in complete Freud’s adjuvant or with purified complex of 600 kd glycoprotein. 
This resulted in development of antibodies against these antigens within 2 weeks. 
The immune complex was demonstrated in the glomerulus in 3-4 weeks, 
proteinuria occurred in 6-8 weeks and nephrotic syndrome developed in 12 weeks 
which continued to persist till they die. Passive Heymann model was induced by 
injecting heterologus anti serum to rat Fx1A or antiserum for megalin. This 
resulted in much rapid onset of the disease when compared to active model. Here 
the glomerular deposits occurred within minutes and proteinuria developed in 7 
day. This phase was known as the heterologus phase as the antibodies deposited in 
the glomerulus were not self. This phase is followed by the autologus phase in 
which autoantibodies are formed against these heterologus antibodies deposited in 
the glomerulus. This resulted in further worsening of proteinuria. However, this 
model could not be induced by immunizing antigens derived from organs other 
than kidneys. Heymann concluded that primary MN had autoimmune basis and 
named membranous nephropathy as “autoimmune nephrosis”. 
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              The histopathological picture of Heymann’s model resembled human MN. 
This made him to believe that human MN could be an autoimmune disease of 
kidney. This was also supported by the coexisistance of MN disease with other 
organ specific autoimmune disease like type 1 diabetes mellitus, myasthenia 
gravis, Graves’ autoimmune throiditis, and primary biliary cirrhosis and so on. 
             Germuth and Dixon proposed that the glomerular deposits were due to 
deposition of circulating immune complex. They believed that these immune 
complexes dissociate, traverse across the glomerular basement membrane, reunite 
and get deposited in the sub epithelial space. On the contrary Van Dame et al and 
Couser  et al demonstrated that ex vivo perfusion of bloodless kidney (which were 
devoid of circulating antigen and immune complex) with heterologus antiFx1A 
antiserum resulted in sub epithelial deposits as that of MN. This suggested that 
antibodies are formed against in situ antigens and not planted antigens or 
circulating immune complexes. This antigen in Heymann’s model was identified as 
megalin.  Surprisingly this is not present in glomerulus of human kidney. Since 
then, various studies were conducted to identify the target antigen in the 
glomerulus. 
Bovine Serum Albumin - related membranous nephropathy: 
           A study showed that few childhood membranous nephropathy patients had 
high levels of circulating cationic bovine serum albumin and anti–bovine serum 
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albumin antibodies. Bovine serum albumin was demonstrated in the immune 
deposits in glomerulus. This bovine albumin is present in cow's milk and beef 
protein .This escapes the intestinal barrier and cause antibody formation. It is of 
cationic charge and binds to the anionic glomerular capillary wall which results in 
immune complex formation. Eliminating this environmental factor from the diet 
may be beneficial in these patients [4].  
 
 Neutral endopeptidase - related membranous nephropathy in neonates: 
 
               Ronco and Debiec by their elegant study demonstrated the target antigen 
in neonatal MN, a rare disease entity in human being. Mothers lacking a podocyte 
membrane protein namely neutral endopeptidase, who were alloimmunized by 
previous pregnancy, delivered new born with MN in subsequent pregnancy. This 
was due to transplacental transfer of antibodies from these sensitized mothers to 
their fetuses resulted in insitu immune complex deposition in them akin to MN. 
This disease is of transient phenomenon as the disease resolves within few months 
after birth with the clearance of these maternal IgG antibodies from the circulation 
[5]. 
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Role of APLA2R1 in the pathogenesis of primary MN: 
         By Western blot technique, Beck et al in 2009 demonstrated that PLA2R1 is 
the major target antigen for idiopathic membranous nephropathy. Phospholipase A2 
Receptor is a 185 KD  type 1 transmembrane receptor of mannose receptor family 
with large extra cellular N terminal domain, small transmembrane domain and 
intracellular C terminal domain .It is expressed on the normal podocytes .This 
receptor exists in two forms; one the extended form and other the bent form.  
Antibody to this receptor has been demonstrated in patients with primary MN .This 
antibody is exclusively of subclass IgG4, which is incapable of activating 
complement cascade .This explains the lack of active inflammation and indolent 
course of primary MN. Antibodies can recognize only the conformation dependent 
target epitope antigen present in the receptors and binding of the antibody occurs in 
one of these two configurations. Normal physiological function of this receptor is 
unknown. It has been suggested that it has a role in positive regulation of mitogen 
activated protein kinase activation and reactive oxygen species production & 
negative regulation by internalization and degradation of PLA2. The triggering 
event that causes this antibody formation and the mechanism of proteinuria 
occurring after antibody binding with this receptor are yet to be identified. 
Formation of in situ immune complex with IgG4 resulted in slow activation of 
complement cascade forming complement membrane attack complex (C5b-9) in 
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sublytic quantities. This gives oxidative stress to the podocytes causing stimulation 
of oxygen radical producing enzymes in the podocytes. Subsequently, cytokines 
including transforming growth factor- beta (TGF-beta) formed as the result of this 
oxidative stress along with complement membrane attack complex (C5b-9) cause 
cytoskeletal alteration in podocytes and abnormalities in slit diaphragm. This 
results in podocyturia and proteinuria [21,22,27,30]. 
              B cells also have a role in pathogenesis of MN possibly acts as antigen 
presenting cells. Immunohistochemistry also demonstrated B cell infiltration in the 
kidney of MN patients [27].  
      By western blot technique, circulating antibodies against this antigen were 
demonstrated in about 70% of patients with primary membranous nephropathy. 
However this technique is not suitable for most diagnostic laboratories for 
analyzing large sample size. To overcome this limitation, in 2011, Hoxha et al 
identified these antibodies by indirect immunofluorescence assay which can be 
used for routine laboratory purposes. He also demonstrated that antibody titers 
correlated with disease severity and response to treatment .He showed that immune 
remission occurred prior to clinical remission. This test is helpful in monitoring the 
disease status and response to treatment. Other method recently developed for 
antibody detection is ELISA. Studies showed that Western blot, ELISA technique 
and indirect immunofluorescence assay had concordant results. 
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            Ronco et al demonstrated enhanced expression of PLA2 receptors in 
podocytes by immunohistochemistry in idiopathic membranous nephropathy 
patients. Out of 31 patients having PLA2R1 positivity, 10 patients had no 
circulating antibody. Rapid clearance of antibody from blood which got deposited 
in glomeruli or late referral of patients with persistent proteinuria due to 
irreversible ultrastuctural changes might be the probable causes. He concludes that 
absence of anti –PLA2R1 antibody does not rule out PLA2R1 associated 
membranous nephropathy. 
           Cumulative data from various studies so far has shown that this assay is 
100% specific for  primary membranous nephropathy as it is not detected in 
patients with secondary membranous nephropathy or in patients with nephrotic 
syndrome of other pathology or in normal individuals .It has sensitivity of 70% to 
80% .This might be due to fluctuating antibody levels with disease activity or 
antigens other than PLA2R1 like superoxide dismutase 2 (SOD 2), aldose 
reductase(AR) and α enolase might be the target in these patients[51,52,53,54]. It 
has been shown by few initial studies that this antibody was positive in some of the 
secondary MN patients like MN due systemic lupus erythematosis or malignancy. 
However later studies showed that these patients found to have only IgG4 subtype 
antibodies in their renal biopsy tissues which is characteristic of primary MN. 
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Hence it was concluded that these patients had primary MN co existing with these 
systemic diseases.  
     Primary membranous nephropathy has 30% to 40% recurrence rate post 
transplant and more so with identification of Anti –PLA2R1 antibody prior to 
transplant. Studies identified these antibodies in 50% to 80% of patients with 
recurrent primary membranous nephropathy and not in de novo membranous 
nephropathy [6]. Advantages of Anti –PLA2R1 antibody estimation is given in 
Table 1. 
Table 1: Advantages of estimating Anti –PLA2R1 antibody  
  Simple non invasive, cost effective method. 
 Avoids extensive diagnostic procedures for ruling out secondary causes. 
 Correlates with disease activity including relapse and severity of disease.  
  Useful for monitoring treatment. 
 Avoids unnecessary exposure to immunosuppressive drugs. 
 Predicts post renal transplant recurrence.  
 Differentiates recurrence from de novo membranous nephropathy.  
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  Even though demonstration of this antibody in patients with nephrotic 
syndrome is diagnostic of primary MN, it would be too early to abandon kidney 
biopsy in such patients. Hofstra et al suggested renal biopsy as the method of 
diagnosing MN. In future, it may be useful as diagnostic biomarker and for 
monitoring response to therapy. Need for the day is developing animal models by 
passive transfer of the a-PLA2R antibody and demonstrating MN in them and 
proving Koch’s postulate for the cause and the effect.  
Pathogenesis of secondary MN is usually due to the circulating immune 
complex or planted antigens. 
 
 
 
 
PATHOLOGY:  
 
 
        Membranous nephropathy derives its name from histopathological feature of 
thickened glomerular basement membrane. In addition, it shows pinholes and 
spikes on JONES silver methanamine staining. All glomeruli show pathological 
changes such that single glomerulus showing spikes is sufficient for diagnosing 
MN [18]. 
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Classical MN shows the following features in histopathology: 
 
 Light microscopy:  
This shows normal mesangium and normal cellularity in the glomerulus; the 
capillary walls are diffusely thickened and capillary lumina are patent; with 
trichome stain it shows subepithelial fuchsinophilic deposits; and in silver 
methanamine staining they show the characteristic spikes pattern.   
 Immunofluorescence microscopy: 
                   Immunofluorescence shows diffuse granular immunoglobulin deposits 
usually IgG and C3, along the capillary walls. Few IgM deposits can be seen 
suggesting non specific entrapment. 
 Electron microscopy : 
                    Electron microscopy shows sub epithelial deposits. Based on the 
location of the deposits MN has four stages. 
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Stage 1:  
Normal by light microscopy, but on electron microscopy, few 
electron-dense deposits is seen in the subepithelial space along 
the capillary walls.  
                 Stage 2:  
Numerous and larger deposits in the subepithelial space with 
spikes from basement membrane are seen on either sides of the 
deposits. 
                  Stage 3:  
New extracellular material surrounds the deposits having chain 
like appearance; electron dense deposit is now surrounded by the 
basement membrane so that subepithelial deposits now become 
intramembranous in position.  
                   Stage 4:  
Resolution phase in which initial electron dense deposits 
become electron lucent, and capillary walls become irregular 
and thickened. 
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Histopathological features that favor secondary MN:  
   
          There are few pathological findings in the renal biopsy that may give us 
some clues to suspect secondary MN 
 
      Lupus nephritis class V: 
     
 presence of  mesangial or endocapillary proliferation  
 
 full house pattern of  immunoglobulin deposits including staining for C1q  
 
in immunofluorescence staining. 
 
 glomerular deposits predominantly containing immunoglobulin other  
 
than IgG4  
 
 electron-dense deposits in the sub endothelial location of the capillary 
wall  
 
 mesangium or along the tubular basement membrane and vessel walls  
 
under electron microscope 
 
 
 endothelial tubuloreticular inclusions under electron microscope 
  
 
Drug-associated secondary MN  
 
  Electron microscope MN shows only a few superficial scattered 
 
 subepithelial deposits       
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Histopathological features as predictors for remission in primary MN: 
 
    
          Few studies tried to assess the histopathological features in renal biopsy as 
predictors for remission in primary MN patients. They showed that neither the 
severity of tubulointerstitial and vascular lesions nor by the degree of complement 
deposition in the glomerulus could predict the remission in these patients. 
 
         In one study, it was observed that in electron microscopy, subepithelial 
homogeneous deposits showed better response to treatment than those with 
subepithelial and intramembranous heterogeneous deposits and this had better long 
term prognosis. But the staging under electron microscope could not predict the 
remission. 
 
Histopathological features as predictors of progression to CKD: 
             Studies showed that presence of chronic irreversible chances in 
histopathology viz. the presence of  tubulointerstitial fibrosis , focal glomeruli 
sclerosis, and chronic vascular sclerosis have been associated with increased risk 
for progression to renal failure . A study conducted in Japan showed that on 
multivariate analysis, tubulointerstitial lesions ≥20 percent of the renal biopsy area 
was one of the significant predictors of progression to end-stage renal disease.   
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             However, they cannot independently predict the rate of disease 
progression. Moreover, baseline clinical variables along with these findings are 
needed to decide upon therapeutic strategy. Similarly, neither the stage nor the 
amount of complement C3 deposition predicts renal survival.  
              Interestingly, these chronic changes in histopathological findings are 
associated with old age, hypertension and lower creatinine clearance at the time of 
presentation. 
 
Clinical Manifestation:  
  
 MN is insidious in nature, takes long time to manifest clinically. It has 
neither prodromal symptoms nor any antecedent trigger like infections. Most 
common presentation is nephrotic syndrome accounting for 60-70%. Proteinuria is 
non selective in MN unlike minimal change disease which has selective 
proteinuria. Approximately 80% of these patients have edema with or without 
features of anasarca. Patients rarely have pericardial and pleural effusions only if 
proteinuria is severe. Patients may also present with nonspecific complaints of 
anorexia, malaise, and fatigue. Thirty to forty percent of patients have subnephrotic 
proteinuria. They are diagnosed in routine evaluation for some other illness. In an 
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unpublished observation, Daniel C. Cattran noted that around 60% of this 
asymptomatic group will progress to nephrotic syndrome over a span of 1-2 years. 
            Microhematuria can occur in 50% of patients with primary MN, but 
macrohematuria is rare. Presence of microhematuria, macrohematuria or RBC cast 
in MN is more likely towards secondary form. Most of these patients have normal 
blood pressure at the time of presentation. Hypertension occurs only in 10-20% of 
patients at the time of presentation. 
 Renal failure at the time of presentation is uncommon accounting for 
around 10-15%. Nephrotic syndrome patients are more prone for thromboembolic 
manifestations and more so in case of MN patients for unknown reasons even after 
adjusting for quantum of proteinuria[7] .MN is the most common cause of renal 
vein thrombosis which can occur in 5 -50%.Other sites of thromboembolism are 
deep vein thrombosis, pulmonary embolism. Occurrence of thrombotic episode 
correlated with disease severity. These are more common in patients with heavy 
proteinuria and severe hypoalbuminemia (<2 g/dl). 
 These patients have high risk for atherosclerotic coronary artery disease due 
to hyperlipidemia. Other clinical manifestations are hypothyroidism, anemia and 
vitamin D deficiency due to loss of corresponding transfer or binding protein in the 
urine. 
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Good prognostic indicators are female sex, children and young adults, 
subnephrotic range proteinuria, a progressive decline in proteinuria, and presenting 
with normal creatinine clearance. In addition, patients belonging to Asian race 
found to have a better long-term prognosis than other ancestries. Attainment of 
remission, either spontaneously or by drugs has good long-term outcome. As 
shown by one study, greater than 50 percent reduction in protein excretion at one 
year has high probability of spontaneous remission.   
      
 
Acute decline in renal function in known primary MN patient: 
             Progressive renal failure in MN typically occurs in more gradual pattern. 
Some patients can have an acute decline in renal function. In such situation, the 
following conditions should be excluded. 
 Acute bilateral renal vein thrombosis which can occur in 5 -50%.This may 
be associated with flank pain, macrohematuria and reduction in renal 
function.  
 Drugs inducing acute interstitial nephritis, such as diuretics, non steroidal 
anti inflammatory drugs and antimalarial drugs in which white cell, white 
cell casts, and possibly eosinophils are typically seen in the urine sediment.  
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 Superimposed crescentic glomerulonephritis, in which red cells and cellular 
casts are found in the urine sediment. Rarely MN can be associated with 
antineutrophilic cytoplasmic antibody associated vasculitis and anti 
glomerular basement membrane disease. 
  Intravascular volume depletion and massive nephrosarca.  
 
 
Secondary MN:  
         Clinical presentation of secondary MN depends on the underlying cause of 
MN. In patients with drug induced MN, proteinuria remits on stopping the 
offending drug (e.g.  gold, penicillamine or nonsteroidal anti inflammatory 
drug).Remission will occur in 9-12 months period , but it may  take even 2-3 years 
for achieving remission. For MN secondarily to autoimmune disease like systemic 
lupus erythematosis, treating the underlying cause will result in remission. Treating 
underlying malignancy or viral infection can cause reduction in proteinuria. 
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Natural history and Prognostic factors:  
        Primary MN can be divided into three groups based on nature history in 
untreated patients (rule of three) [25,46].   
 Spontaneous remission of proteinuria occurs in 5-30% at 5 years 
 Persistent proteinuria with stable renal function occurs in 25- 40 % at 5 years  
 Progressing to end stage renal failure occurs in 14% at 5 years, 35% in 10 
years and 41 % in 15 years. 
      As significant numbers of patients have spontaneous remission, in the view 
of unacceptable toxicity of the drugs used to primary MN, it is advised to 
continue conservative line of management for reasonable duration so as to 
achieve spontaneous remission.   
 
 Predictors for progressing to end-stage renal disease:  
              Prognosticating any disease is very essential for deciding the management 
strategy.  An accurate predictor of renal outcome of patients in primary MN may 
be helpful for separating patients who are likely for progressing to renal failure. 
This would prevent low risk group from exposure to the toxic immunosuppressant 
drugs. But till now no such accurate predictor exist for primary MN patient. The 
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following are clinical and biochemical parameters that may be used as predictors 
for progression to end stage renal failure [32,47,48,49]. 
  older age at onset (particularly greater than 50 years)  
 male sex 
 nephrotic range proteinuria (particularly if protein excretion exceeds 8 to 10 
g/day)  
 lower  initial creatinine clearance [sr. creatinine ≥1.5 mg/dL (≥133 
micromol/L)]   
  the rapid rate decline in creatinine clearance 
              Toronto Glomerulonephritis Registry defines risk for progression to renal 
insufficiency in patients with primary MN. Based on quantum of proteinuria and 
creatinine clearance at the time of presentation, they classify patients as low, 
moderate and high risk (Tab.2).Low risk patients has less than 10% chance for 
progressing to end stage renal disease in 10 years as compared to high risk patients 
having as high as 80% probability for progressing to end stage renal disease at the 
end of 10 years.  
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    Table .2: Toronto Glomerulonephritis Registry risk stratification. 
 
RISK 
 
uPCR (mg/mg) 
GFR 
(ml/min/1.73 m2) 
% of progression to 
ESRD(10 yrs) 
Low <4 >60 <10% 
Moderate 4-8 >60 55% 
High >8 >60 or < 60 66-80% 
            This stratification is meant for progression to chronic renal disease only. 
This will not hold good for other complications of nephrotic syndrome like 
atherosclerosis due to hypercholesterolemia and thromboembolic complications 
due to the hypercoagulable state. 
           As per van den Berg in his study urinary biomarkers such as α1 
microglobulin, β 2- microglobulin, are comparable to quantum of proteinuria in 
predicting the patients who are at risk for progression to end stage renal failure. 
But non availability of these markers limits their clinical utilization [21,33]. 
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MANAGEMENT 
 
Investigations: 
 
             It is of paramount importance to differentiate primary from secondary MN 
as the therapeutic protocol differ entirely for them. Secondary MN remits by 
treating the underlying cause but primary MN may need toxic immunosuppressant 
drugs. Following investigations are done as and when MN is diagnosed in the renal 
biopsy. 
           Urine analysis: 
       Urine microscopy: 
 For any red blood cells and red blood cells cast. 
  
 Quantification of urinary protein excretion. 
 
- uPCR or 24 hours urine protein estimation. 
Blood urea nitrogen, serum creatinine and creatinine clearance. 
Liver function test. 
Antinuclear antibodies, anti–double-strand DNA, complement levels. 
Hepatitis B, hepatitis C serology. 
Syphilis serology. 
Lipid profile. 
 
39 
 
Malignancy workup: 
Age and gender appropriate health screening such as, mammography, 
motion for occult blood, upper gastrointestinal endoscopy, 
sigmoidoscopy, X ray chest, prostate specific antigen. 
Other investigations according to clues from the initial patient history 
and physical examination.  
 
Newer  investigations. 
                  Antiphospholipase A2 receptor antibody assay 
                                   For diagnosis and monitoring therapy 
                     Urinary biomarkers for risk stratification 
 IgG excretion rate. 
 
 Urinary beta-2 micro globulin [33]. 
  
 Urinary C5b-9 [21]. 
 
 
Treatment of primary MN:  
 
            Goal of treating primary MN is to preserve the renal function by reducing 
the proteinuria and minimizing complications from nephrotic syndrome. It is a 
known fact that about one third of MN undergoes spontaneous remission. Hence 
not all patients require immunosuppressant drugs .Also these drugs have serious 
adverse effect. Risk and benefit of treating with immunosuppressant drugs should 
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be weighed before starting on these drugs. Most of the time, it is difficult to make 
decisions regarding treatment protocol [16].  
Conservative treatment: 
        As discussed previously, there is high rate for spontaneous remission in 
primary MN patients. Only those patients with high risk for progression to renal 
failure or those having complications of nephrotic syndrome should receive potent 
immunosuppressive treatment. But all most all patients are candidates for 
conservative therapy. Conservative therapy includes angiotensin inhibition, lipid-
lowering and anti coagulants in selected patients .Other supportive therapy 
includes control of edema with anti diuretics and nutrition support [46].   
RAAS inhibition: 
            Renin angiotensin adosterone inhibitors are recommended in all most 
all patients with MN for reducing proteinuria. It acts by lowering the 
intraglomerular pressure by inhibiting angiotensin mediated efferent arteriolar 
vasoconstriction. They are also recommended in chronic kidney disease patients 
having proteinuria along with monitoring serum potassium level. The optimal 
proteinuria goal in patients with chronic kidney disease is less than 1000 mg/day. 
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But this is difficult to achieve in MN patients. Though it reduces proteinuria, 
studies show that it does not alter the course of the disease.  
The evidence for a renal protective effect with ACE inhibitors or ARB is 
relatively weak in MN patients. Achieving partial remission is helpful, as studies 
has shown that partial remission by itself was independently associated with  
slower decrease in renal function and a lower incidence of renal failure in long run. 
Target blood pressure: 
      As in other proteinuric kidney diseases, optimum blood pressure would 
be less than 130/80 mmHg. By attaining this target blood pressure, progression to 
chronic kidney disease is reduced. Reduction in blood pressure has two advantages 
i) reduction in proteinuria, ii) significant reduction in cardiovascular risk (as these 
patients are associated with high risk for cardiovascular disease). 
 A low salt diet is an important part of antihypertensive therapy (especially 
when using angiotensin inhibitors) and control of edema in patients with MN. 
Also, a high salt diet can increase proteinuria. In some individuals, a high salt diet 
would be the cause of worsening proteinuria rather than increased immunological 
activity reaction. 
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Other drugs including diuretics for correcting volume overload may reduce 
blood pressure. Diuretics cause symptoms like fatigue, orthostatic hypotension or 
decreased tissue perfusion as evidenced by elevation in the blood urea nitrogen 
and/or serum creatinine concentration as adverse effects.  
 Lipid lowering drugs. 
        Hyperlipidemia   occurring due to nephrotic syndrome is a risk factor 
for cardiovascular disease in MN patients. Elevation in the serum cholesterol 
concentration is treated by statins which has pleotropic effect including endothelial 
protection and reducing cardiovascular disease.  
 Anticoagulants. 
          Patients with nephrotic syndrome due to MN in particular are at 
increased risk for thromboembolic events .This risk increases drastically in patients 
with serum albumin of less than 2.5 g/dl. KDIGO suggests prophylactic 
anticoagulation in these patients or those who developed deep vein thrombosis. 
Initially these patients should be treated with low molecular weight heparin or 
unfractionated heparin followed by oral anti coagulants.   
 
 
43 
 
Immunosuppressive Therapy: 
   Immunosuppressive drugs are indicated only for patients under high 
risk group as per Toronto risk group stratification. Various immunosuppressive 
drugs have been tried for primary membranous nephropathy patients. First-line 
immunosuppressive therapy consists of cytotoxic drugs like alkylating agents plus 
glucocorticoids .If alkylating agents are contraindicated, calcineurin inhibitor with 
low dose glucocorticoids is given [35]. Patients who do not respond to one regimen 
are usually treated with the other, and those with resistant disease may be treated 
with Rituximab. Adrenocorticotropic hormone has also been tried in few studies. 
 Alkylating agents: 
   Ponticelli regimen is used for treating patients under moderate to high 
risk category [31, 55, 56]. This regimen includes Methyl prednisolone 1 g 
intravenously once daily for 3 days followed by oral prednisolone 0.5 mg/kg for 27 
days .This is followed by Chlorambucil orally for 30 days at a dose of 0.2 mg/kg. 
This constitute for one cycle. This is repeated for 3 cycles. Five and ten year’s 
remission was 40 % and 47% and 5 and 10 years ESRD were 10% and 40% 
respectively. In modified Ponticelli regimen Chlorambucil is replaced by 
Cyclophosphamide at a dose of 2 mg/kg orally. Jha et al from India also compared 
this regimen with supportive treatment and followed up for 10 years. This study 
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also confirmed results of Ponticelli. There are both short and long term toxicities 
for cyclophosphamide. Short term toxicities include bone marrow suppression, 
infection, alopecia, cystitis, seizures. Long term toxicities include cancer like non 
melanocytic skin malignancy and bladder cancer and infertility in men and women. 
Table.3: Trials including alkylating agents in primary MN [46]. 
 
 
 
 
Trial Treatment Follow up 
(months) 
Remission Renal survival 
Ponticelli (RCT) Chlorambucil & 
Prednisolone 
120 83 vs. 38 92 vs. 60 (10 yr) 
Jha (RCT) Cyclophosphamide & 
Prednisolone 
130 72 vs. 24 89 vs. 65(10yrs) 
Torres Chlorambucil & 
Prednisolone 
48 42 vs. 0 90 vs. 20 (7 yrs) 
Du Buf Cyclophosphamide & 
Prednisolone 
51 86 vs. 20 86 vs. 32 (5 yrs) 
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Calcineurin inhibitors: 
                               Few studies showed the efficacy of both Cyclosporine and 
Tacrolimus in patients with primary MN in reducing proteinuria and prevention of 
progression to ESRD when combined with steroids. One study by Cattran et al 
showed that Cyclosporine at 3.5 mg/kg/day for 12 months reduces proteinuria by 
50% in 50% of patients and may slow progression the progression of renal failure. 
The relapse rate was about 50% after discontinuing the drug. 
        Regarding Tacrolimus, study done by Chen et al showed that Tacrolimus with 
steroids has equal efficacy to that of cyclophosphamide with steroids. But there is 
increased incident of adverse effect like diabetes mellitus, hypertension and 
infection in patients treated with Tacrolimus. 
  
Mycophenolate mofetil: 
           Pilot studies done by Chan , Nayagam and Branten et al  showed that 
MMF is not inferior to cyclophosphamide in treating primary MN patients. 
Long term effect of this drug is not known. Randomized control trials are 
needed using MMF to decide up on its role in these patients. KDIGO does not 
recommend MMF as monotherapy in primary MN patients [10,11,20]. 
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Rituximab: 
          Rituximab is anti B cell (CD 20) monoclonal antibody. Studies have shown 
that Rituximab effectively reduced the proteinuria in patients with primary MN 
more so if they are resistant to first line drugs. Ruggenenti et al showed that 
patients having minimal interstitial fibrosis and tubular atrophy had good response 
to this drug compared to those with severe interstitial fibrosis and tubular atrophy. 
Anti APLA2R antibody titer was reduce after   Rituximab therapy.The major 
alarming side effect of this drug is progressive multifocal leucoencephalopathy 
which occurred in 80% of the patients receiving this drug [11,12,13,14,15].  
 
Adrenocorticotropic hormone: 
                Berg et al in his publication in 2009, in 30 patients who received ACTH 
had reduction in proteinuria and improvement in serum albumin during a follow up 
of 3- 13 years. He concluded that ACTH therapy is equally efficacious as that of 
methyl prednisolone and alkylating agent. Few follow up studies also showed 
promising results. Till now there is no randomized control trial for ascertaining its 
position in the management of primary MN.           
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             Guidelines for management of MN 
Biopsy proven MN  
 
 APLA2R AB     R/O secondary causes  
    
        
  
< 4 g/d                           4-8 g/d  & Crcl-N                       >8 g/d  renal failure (Crcl >30 ml/min/1.73 m2) 
 
Supportive                     Supportive 6 months                 
 
                                                           
               
                                                                     
)                                                                                                  
 
                  P.R                                        C.R   
 
 
 RESISTANT        
 
            
CNI                                                       FOLLOW  
CR : Complete Remission  , PR :Partial Remission  , CNI : Calcineurin Inhibitors, 
MP: modified Ponticelli Regimen 
   Primary MN 
    No Remission Remission   
      Immunosuppression 
 CNI (1YR) 
Alkalyting agent(m.P) 
No Remission                                         PR CR             No Remission                                         PR CR 
Resistant   Supportive Resistant   Supportive 
 Alkylating agent Follow Up                     CNI Follow Up                     
48 
 
Relapse   :   
             Sub nephrotic proteinuria - supportive treatment 
             Nephrotic syndrome - Repeat initially responded regimen only once  
 
Indication for repeat biopsy:    Rapid rise in sr. creatinine (30% in 2 months) 
 
Supportive treatment: 
                                              Antiproteinuric drugs  
                  Antihypertensive drugs  
                                              Lipids lowering drugs  
                                              Anticoagulant prophylaxis (if sr.albumin < 2.5 g/dl) 
 
Prophylaxis for long term steroids: 
                                     Pnemocystis jeroversi prophylaxis 
                         Osteoporosis 
Second line drugs: 
                                     Rituximab. 
                                     Adrenocorticotropic hormone (ACTH). 
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MATERIALS AND METHODS: 
 
          Institutional ethical committee approval was obtained for the study. This is 
prospective observational study conducted during the period of March 2012-
February 2014 in the Department of Nephrology, Madras medical college, 
Chennai.  
 
INCLUSION CRITERIA:  
 Age between 12 -75 yrs 
 Biopsy proven membranous nephropathy patients.  
 
 
EXCLUSION CRITERIA: 
 Pregnant patients 
 Unwilling patients 
 End stage renal disease patients (e GFR < 30 ml/min/1.73 m2) 
. 
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Patients with biopsy proven MN, who got treatment under our department 
within the study period, were included in the study. Detailed clinical history of 
edema, oliguria, abdominal distension and other relevant history were taken. 
History suggestive of secondary causes like joint pain ,early morning stiffness, skin 
rash, photosensitivity, breathlessness, for connective tissue disorders, loss of 
weight, and appetite, swelling anywhere in the body, hemoptysis, hematemesis, 
vomiting, alerted bowel habits for malignancy, past or recent history of jaundice, 
blood transfusion for hepatitis B, and other detailed drug history was obtained. 
Other history includes history regarding comorbid illness and personal history. 
Detailed clinical examination including blood pressure examination in all 4 limbs 
and complete systemic examination were done. Those with blood pressure >140/90 
were diagnosed to have hypertension. 
    Patients were subjected to routine urinary examination including urine for 
protein, deposits like red blood cell, white blood cell. Urine was analyzed for red 
blood cell cast, white blood cell cast also. Urine protein/creatinine ratio was 
measured. Patients underwent routine hematological investigation like blood 
hemoglobulin, total count, differential count, peripheral smear study. Blood 
investigation viz. blood sugar, blood urea, serum creatinine, serum electrolyte, 
lipid profiles were taken. GFR estimated by Cockcroft Gualt equation 
(ml/min/1.73 m2). Liver function test including serum bilirubin and liver enzymes 
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were taken. .Urine for culture and sensitivity, blood for culture and sensitivity and 
for malarial parasites were done. All patients screened for viral serology like 
hepatitis B, hepatitis C infection and human immunodeficiency virus. Appropriate 
patients were screened for other serological markers including antinuclear 
antibody, anti double stranded-DNA, complement levels. Chest X ray PA view and 
electrocardiography, upper gastrointestinal endoscopy and motion for occult blood 
were done in all patients. Ultra sonogram of abdomen, ultra sonogram kidney and 
urinary tract done for assessing size of kidney, cortical echogenesity, and 
corticomedullary differentiation was done. Appropriate patients were also screened 
for C.T chest, prostate specific antigen for males and mammography for female 
patients.  
   Histopathological features of renal biopsy at the time of presentation including 
C1q staining and interstitial nephritis and tubular atrophy were noted. 
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ANALYSIS: 
              Biopsies proven MN patients were categorized into primary and 
secondary after screening for secondary causes. Secondary MN patients were 
labeled according to the underlying cause. Both the groups were analyzed under 
clinical biochemical and histopathological parameters. 
      In primary MN group, patients were treated according to KDIGO guidelines 
their remission rates were assessed. The clinical biochemical and histopathological 
parameters were analyzed both in patients who achieve remission and those who 
did not. All the primary MN patients were followed up regularly. Patients who 
progress to end stage renal disease were assessed and the predictors of were 
analyzed. 
 
Clinical data: 
Patients were categorized into three groups according to their risk of 
progression to chronic kidney disease. Low risk was defined as urine protein 
creatinine ratio (uPCR) < 4mg/mg and eGFR > 60 ml/min/1.73m2 using Cockcroft 
Gualt formula. Moderate risk included uPCR 4-8 mg/mg and eGFR > 60 
ml/min/1.73 m2 and high risk as uPCR >8 mg/mg and eGFR < 60ml/min/1.73 m2. 
Remission was defined as > 50% reduction in proteinuria and uPCR of <3.5 
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mg/mg.In histopathology, based on degree of interstitial nephritis and tubular 
atrophy patients were categorized into three groups viz.1+ is <25%, 2+ is denotes 
25%-50% and >50% as 3+.C1q staining was reported as negative,1+,2+ and 3+ 
depending on the intensity of staining in immunofluorescence.  
STATISTICAL ANAYSIS PLAN: 
For data description, continuous variables with symmetric distribution were 
presented as the mean ± SD. Student’s t- test and analysis of variance (ANOVA 
single factor) were used for parametric analysis. Categorical variables were 
described as frequencies or percentages, and the data were analyzed with Chi-
Square tests. All of the statistical analyses were conducted using SPSS, version 
16.0. 
 
 
 
 
 
 
 
 
54 
 
RESULTS 
 
Profile of our study population: 
           A total of 98 patients with biopsy proven membranous nephropathy (MN) 
were included in the study. Of which 5 patients who presented with end stage renal 
disease at presentation were excluded. Ninety three patients were included in the 
study. After screening for secondary causes 56/93 (60%) were diagnosed as 
primary MN and remaining 37/93 (40%) were secondary MN. The underlying 
causes of secondary MN patients were lupus nephritis (N=28), malignancy (N=3), 
hepatitis B virus (N=2) rheumatoid arthritis (N=1), and native drugs (N=3) (native 
drugs were presumed to be the etiology, considering the temporal relationship 
between the consumption of native drugs and onset of proteinuria) {Tab: 4}. Mean 
age of presentation was 39.6 years; 55% (51/93) of them were males. The mean 
serum creatinine and eGFR were 1.1 mg/dl and 73.4ml/min/1.73 m2 respectively. 
Mean uPCR was 4.27 mg/mg; sixty nine percent (64/93) of patients had nephrotic 
proteinuria; mean serum albumin was 3.2 g/dl and mean serum cholesterol was 
208mg/dl.  
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 Table.4: Spectrum of secondary MN: 
s.no. Secondary MN   (Total - 31) Percentage 
1 Lupus nephritis 28(75.6%) 
2 Malignancy 3(8%) 
3 Drugs 3(8%) 
4 Hepatitis B 2(5.4%) 
5 Rheumatoid arthritis 1(2.7%) 
TOTAL 37 
                                         
 
Clinical and laboratory parameters of primary and secondary MN: 
 
       Table 5 and Table 6 show the clinical characteristics and laboratory parameters 
of MN patients at the time of presentation. On comparing the age distribution, most 
of our primary MN patients were within 40-60 years of age 55% (31/56) and most 
of the secondary MN group were outside this range 78% (29/37) which is 
statistically significant (p=0.0012). Sixty six percent  (37/56) of them were males 
in primary MN group but in secondary MN majority of them were females 62% 
(23/37) which was statistically significant(p=0.007). Primary MN patients had 
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severe disease at the time of presentation when compared to the secondary MN 
patients in the form of proteinuria, serum albumin and serum cholesterol. Edema 
was present in significant number of patients in primary MN (p=0.016). Primary 
MN  patients had severe proteinuria when compared to those with secondary MN 
(uPCR, 4.75mg/mg vs.3.60 mg/mg, p=<0.001).The serum albumin level was  low 
in primary MN patients (3.07g/dl vs.3.49 g/dl p=<0.001) and serum cholesterol 
was significantly high (224 mg/dl vs. 184mg/dl  p=<0.001).Significant proportion 
of secondary MN patients  had microhematuria than those with primary MN  
(40.5% vs. 12.5% p=0.0018).However there was no significant difference in 
estimated GFR among both the groups. 
     
 
TABLE.5: Clinical profile of MN. 
s.no Variables Primary MN Secondary MN p value 
 TOTAL 56 37  
1 Age  41.05±10.2 37.32±11.18 0.1005 
2 Age in 40 to 60 yrs 31 8 0.0012 
3 Male 37 14 0.007 
4 Diabetes mellitus  1 3 0.141 
5 Hypertension 7 7 0.396 
6 Edema 41 18 0.016 
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Table.6: Laboratory profile of MN 
s.no Variables primary Secondary p value 
 TOTAL 56 37  
1 Hemoglobin (g/dl) 11.8±2.4 11.5±2.3 0.429 
2 Hematuria 7 15 0.002 
3 u PCR (mg/mg) 4.75±1.5 3.6±0.96 <0.001 
4 Nephrotic proteinuria 42 22 0.114 
5 Sr. creatinine (mg/dl) 1.12±0.38 1.23±0.93 0.414 
6 e GFR (ml/min/1.73 m2) 74.5±22.8 72.2±24.9 0.640 
7 Sr.albumin(g/dl) 3.07±0.62 3.49±0.47 <0.001 
8 Sr. total cholesterol (mg/dl 224±23.6 184±47 <0.001 
9 Random Blood sugar(mg/dl) 106.4±23.6 107±27.8 0.900 
 
 
Biopsy profile of primary MN and secondary MN: 
      Biopsy of primary MN and secondary MN patients were compared based on 
C1q staining in immunofluorescence. 57 %( 21/37) of secondary MN had at least 
1+ C1q staining when compared to 7 %( 4/56) in those with primary disease. On 
comparing the intensity of staining, 46 %( 17/37) of secondary MN patients had      
> 1+ intensity but none of the primary MN had > 1+ staining. {Tab: 7} 
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Table.7: Histopathology of MN: (C1q staining in IF only) 
Variable Primary MN Secondary MN p value 
 
C1q Staining 
0 52 16  
 
0.049 
 
1+ 4 4 
2+ 0 9 
3+ 0 8 
Total   93 56 37 
IF – Immunofluorescence. 
 
 
Analysis of remission rate of primary MN: 
 
          To assess the correlation between the initial clinical presentation and 
remission rate, we followed up all the idiopathic MN patients. Secondary MN 
patients were excluded from the analysis as the remission depends on the 
underlying cause. Median follow up period was 18 months (6 - 24 months). All the 
study subjects received RAAS (rennin angiotensin aldosterone system) inhibitors.   
Immunosuppressive therapy was started in indicated patients as per KDIGO 
guidelines. Out of 56 primary MN patients, 33 (59%) received the modified 
Ponticelli (m.P) regimen. Strict adherence to the regimen was ensured. Remaining 
23 patients had not received immunosuppressive therapy. Fourteen of them were 
under mild risk category hence immunosuppressant drugs were not indicated at 
that time. They were treated conservatively with RAAS inhibitors and other 
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supportive drugs. Among the remaining 9 patients, three discontinued the regimen 
due to serious infections, three were non compliant to the regimen, two  were not 
willing for any treatment and one was started on calcineurin inhibitor based 
regimen as she was planning to become pregnant in near future . All the patients 
were on regular follow up.   Out of 56 primary MN patients, 30 % (17/56) of 
patients achieved   remission. Out of 33 patients who received modified Ponticelli 
regimen 24 % (8/33) achieved remission. Spontaneous remission occurred in 9 out 
of these 14 patients (64%) who were under conservative therapy. There is no 
statistical significance of remission in both the group (p=0.67) {Table.8}.  
 
Table.8: Remission and modified Ponticelli regimen. 
 Received m.P Not received m.P Total p value 
Remission achieved 8 9  17  
0.670 
 
 
Remission not achieved 25 14 39 
Total 33 23 56 
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Adverse effects during modified Ponticelli regimen: 
                    Gastrointestinal infection occurred in 2 patients, lower respiratory 
infection in 3, drug induced DM in one patient and allergic reaction in one patient. 
All these patients recovered completely after receiving appropriate treatment. 
 
Correlation between the initial clinical presentation and remission rate 
in primary MN: 
 
      We tried to analyze whether the clinical or laboratory parameter at the time of 
initial presentation predicts remission in primary MN patients. Patients having 
severe disease at the time of presentation had poor remission rate (both in 
conservative and immunosuppressive therapy) when compared to that with mild 
disease. Patients who had not remitted had severe proteinuria (uPCR 5.3 mg/mg vs. 
3.3 mg/mg p=<0.001).Also serum albumin in them was significantly lower (2.8 
g/dl vs. 3.47 g/dl p=<0.001) and serum cholesterol was significantly high 
(241mg/dl vs.184mg/dl p=0.0017).But creatinine clearance showed no significant 
difference between the groups (72.41 ml/min/1.73m2 vs.79.9 
ml/min/1.73m2).{Table.9 & 10}  
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Table.9: Initial clinical presentation and remission.  
s.no Variables Remission 
present 
Remission 
absent 
p value 
 TOTAL 17 39  
1 Age 39.8±8.3 41.59±11 0.557 
2 Male 11 26 0.877 
3 Diabetes mellitus 1 0 0.125 
4 Hypertension 3 4 0.439 
5 Edema 10 31 0.107 
 
Table.10: Initial laboratory parameters and remission.  
s.no Variables Remission 
present 
Remission 
absent 
p value 
 TOTAL 17 39  
1 Hemoglobin (g/dl) 12.7±1.94 11.5±2.58 0.104 
2 Hematuria 3 4 0.440 
3 u PCR (mg/mg) 3.31±1.35 5.33±1.22 <0.001 
4 Nephrotic proteinuria 5 37 <0.001 
5 Sr. creatinine (mg/dl) 1.12±0.38 1.03±0.29 0.352 
6 e GFR (ml/min/1.73 m2) 72.2±21.1 79.98±22.6 0.246 
7 Sr.albumin(g/dl) 3.47±0.47 2.80±0.57 <0.001 
8 Sr. total cholesterol (mg/dl 184.2±26.3 241.8±69.4 0.0017 
9 Random Blood sugar(mg/dl) 103±25.06 107.9±23 0.481 
10 Immunosuppressant drugs 8 9 0.670 
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 Histopathology of initial biopsy and remission in primary MN. 
         In order to assess the correlation between the histopathological features of 
initial biopsy of the kidney and the remission among primary MN patients, we 
compared the degree of interstitial fibrosis of those achieved remission and those 
who had not remitted. Out of 17 patients who achieved remission, 59% (10/17) had 
no interstitial fibrosis and tubular atrophy and out of 39 patients who had no 
remission 60% (23/39) had no interstitial fibrosis and tubular atrophy. None of the 
patients who achieved remission had severe interstitial fibrosis and tubular atrophy 
(> 50%) and 13% (5/39) of those who had no remission had severe interstitial 
fibrosis and tubular atrophy .Though severe interstitial fibrosis and tubular atrophy 
was more with those who had not achieved remission this could not statistical 
significance.{Table.11}  
Table.11: Histopathology and remission in primary MN.  
(Compared only interstitial fibrosis and tubular atrophy in light microscope.) 
Variables Remission 
present 
Remission 
absent 
p value 
 
Interstitial fibrosis 
& 
Tubular atrophy 
0 10 23  
0.439 1+ 5 11 
2+ 2 0 
3+ 0 5 
TOTAL       (56) 17 39 
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Comparison of variables between CKD and stable renal function. 
          In order to evaluate whether the initial clinical, laboratory and 
histopathological parameters could predict the progression of renal failure, we 
compared these variables between those who had stable renal function and those 
progress to renal failure. During the follow up of 56 primary MN patients, 10 % 
(6/56) of them developed progressive renal failure. Out of the 6 patients who 
progressed to renal failure, 67% (4/6) had interstitial fibrosis and tubular atrophy of 
>25% when compared to 6% (3/50) in those who had stable renal function. Hence 
those patients having severe interstitial fibrosis and tubular atrophy (> 25 %) at the 
time of presentation progressed to renal failure during the follow up period. Five 
out of 6 (83%) patients progressing to renal failure had nephrotic proteinuria as 
compared to 37 out of 50 patients (74%) having stable renal function. One patient 
among the group progressed to renal failure had remission (16%) as compared to  
16 out of 50 (32%) in stable renal function group. Though statistically not 
significant, proportion of patients having nephrotic proteinuria and reduced 
remission rate had high probability for progressing to renal failure.{Table.12}  
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Table.12: Comparison of variables between CKD and stable 
renal function. 
 
 
 
 
 
 
 
 
s.no Variables CKD 
present 
Stable renal 
function 
p value 
 TOTAL 6 50  
1 Age 43.3±11.6 40.7±10.1 0.56 
2 Male 5 22 0.34 
3 Hypertension 0 7 0.32 
4 Hemoglobin (g/dl) 10.4±2.9 12±2.3 0.13 
5 Hematuria 3 4 0.003 
6 u PCR (mg/mg) 5.06±1.8 4.67±1.5 0.578 
7 Nephrotic proteinuria 5 37 0.617 
8 Sr. creatinine (mg/dl) 1.6±0.59 1.1±0.35 0.386 
9 e GFR (ml/min/1.73 m2) 74.3±30.5 74.6±22 0.605 
10 Sr.albumin(g/dl) 0.61 3.03±0.62 0.353 
11 Sr. total cholesterol (mg/dl 275±88.7 218±60 0.041 
12 Random Blood sugar(mg/dl) 113±39.94 105.6±21.38 0.434 
13 Severe interstitial fibrosis 
&tubular atrophy (>25%) 
4 3  <0.001 
14 Remission 1 16 0.439 
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Fig.1: Spectrum of membranous nephropathy. (Total 93)
 
Fig.2: Sex  ratio. 
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Fig.3: Clinical features of statistical significance  at the time of presentation. 
 
 
Fig.4: C1q staining in primary and secondary MN 
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Fig.5: Clinical features at the initial presentation and remission 
 
 
Fig.6: Outcome after modified Ponticelli regimen. 
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Fig.7: Histology and CKD progression 
 
 
 
Fig.8: Remission and CKD progression  
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DISCUSSION 
                In our study 60% of study population were idiopathic MN and 40% were 
secondary MN supporting the fact that primary is more common than the 
secondary MN .Among the secondary MN, lupus nephritis was constituting the 
most, of 75.6% of cases. Sixty six percent (37/56) of primary MN patients were 
males and majority of the secondary MN were females accounting for 62% 
(23/37). Hence, females are more likely to have secondary MN as compared to 
male. But in our study, lupus nephritis was the major contributor of secondary MN, 
accounting for 75% which is more common in females.  
              On analyzing the age, as per previous studies, usual age of presentation of 
primary MN is in the fourth and fifth decade. In our study also, 55% (31/56) of 
primary MN patients were within the range of 40-60 years of age. But among the 
secondary MN patients, 78% (29/37) was outside this range which was statistically 
significant. This shows that patients presenting outside the usual range of 40-60 
years more likely to have secondary MN. 
           Primary MN patients had severe disease in our study. Pedal edema was more 
common among primary MN than in secondary MN. Also, proteinuria, 
hypoalbuminemia and hypercholesterolemia were severe among the primary MN 
patients. Seventy five percent of patients in primary MN presented with nephrotic 
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proteinuria. Forty percent (15/37) of patients presented with microhematuria 
among the secondary MN group as compared to 12% (7/56) in primary MN group. 
Though microhematuria can occur to a maximum of 50% in patients with primary 
MN, our study suggests screening for secondary cause before concluding these 
patients as primary. Patients having severe disease are more likely to have primary 
MN. However, there was no significant difference in the creatinine clearance 
between the two groups at the time of presentation.  
            Immunofluorescence staining of primary MN is usually IgG and C3. 
Studies show that staining for other deposits like C1q suggests secondary MN. Our 
study also confirms this notion. Fifty eight percent (21/37) of secondary MN in our 
study had positive for C1q staining as compared to be 7% (4/56) in primary MN 
patients which is significant statistically(p=). Also, the intensity of staining is more 
in secondary than in the primary MN. Forty six percent (17/37) of secondary MN 
had more than 1+ staining for C1q as compared to none in the primary MN 
patients. Intense C1q staining in the histopathology of kidney biopsy in MN patient 
suggests secondary form of MN. 
          
            Among the total 56 primary MN patients, 30.5% (17/56) achieved 
remission. Though our study was not designed for assessing the effectiveness of 
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the disease specific therapy (modified Ponticelli regimen), we compared the rate of 
remission in those patients who received this therapy and those treated 
conservatively. The modified Ponticelli regimen included 6 months therapy of 
steroid and oral cyclophophamide on alternate months. Remission was achieved in 
24% (8/33) of patients immediately after completing the regimen. Forty percent 
(9/23) of remaining 23 patients on conservative treatment had remission. 
   Various studies have shown that remission can occur even months after 
completion of this regimen. KDIGO also holds the view that, it is reasonable to 
wait for 12 -18 months after the immunosuppressive therapy before concluding 
that initial therapy has been ineffective. At  this juncture it would be worth mention 
the role of Apla2r in assessing the remission .Studies  showed  that in primary MN 
patients, anti APL2R antibody starts reducing and disappear (immunological 
remission) much earlier than that of remission of proteinuria (clinical 
remission).This would prevent unwarranted exposure of patients  to these  toxic 
immunosuppressant  drugs . But it is rather intriguing to address the question – 
would it be justified to tailor immune therapy according to the immunological 
reactivity. Randomized controlled trials are need for answering this question. 
  Our study also demonstrated that patients having severe disease had lesser 
chance of remission when compared to milder category. Proteinuria, 
hypoalbuminemia and hypercholesterolemia had inverse relationship to the rate of 
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remission (conservative and immunosuppressive therapy combined).There is no 
difference in creatinine clearance among the two groups. The small sample size of 
this subcategory has made the analysis difficult. However, apparently there exists 
good correlation between the severity of disease and low creatinine clearance at the 
time of presentation and rate of remission. 
  Our study also confirms the previous notion that degree of interstitial 
fibrosis and tubular atrophy in the biopsy done at the time of initial presentation do 
not have an influence over rate remission. 
          As we know that one third of patients will progress to renal impairment, it is 
essential to identify such high risk patients at the time of presentation enabling 
them to start on intense therapy. This will avoid unnecessary exposure of toxic 
drugs to the remaining two third of patients. Degree of proteinuria and urinary 
level of C5-9 and β 2 microglobulin and serum creatinine were used by few 
authors for risk stratification. We tried to analysis the epidemiological, clinical, 
biochemical and histopathological parameters as predictors of progression to renal 
impairment. 
  In our observation, 10% (6/56) of primary MN patients progressed to 
chronic renal disease in our population. Presence of interstitial fibrosis and tubular 
atrophy of >20% in the biopsy done at the initial time of presentation, was good 
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predictor for progression to chronic renal disease in our study population. 
Progression to chronic kidney disease was more with those patients having 
proteinuria of > 3.5 mg/mg creatinine and those who had not remit either by 
conservative or by immunosuppressive drugs though it was not statistically 
significant. We could not achieve significance statistically as the sample size of 
subcategory is very small. 
     
 
Limitations: 
          There are few limitations in our study. Our study group is of limited size. 
Study is as a prospective single centre observational study. Patients were followed 
up for a short period. Remission of proteinuria was assessed immediately after 
completing the modified Ponticelli regimen. Patients not remitted during this study 
may remit after the study period. We could not assess the APLA2R activity for 
study population which would further support our differentiation into primary and 
secondary MN. 
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                                      Conclusion 
 
 Primary MN was more common than secondary MN in our study 
accounting for about 60%. 
 
 On comparing the variables, the observations were as follows.  
                      i) Age: 
                   - Primary MN was common in between 40-60 years   
                   - Secondary MN was outside this range  
                     ii) Sex: 
- Males were common in primary MN 
- Females were common in secondary MN. 
iii) Primary MN had severe disease at the time of presentation in the  
     form of      
- Presence of edema, severe proteinuria, 
hypoalbuminemia and hypercholesterolemia 
     iv)  C1q staining in the biopsy was  more common in secondary MN. 
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                  Though the type of MN may be suspected to some extent by these 
clinical, biochemical and pathological features, they individually cannot 
differentiate primary from secondary MN. Combining all these parameters along 
with the search for secondary causes and detection of APLA2R antibody will help 
in this regard. 
 
  Remission is less likely in patients having severe disease at the time of 
presentation. The degree of interstitial fibrosis and tubular atrophy has no 
effect on remission in these patients. 
 
 Interstitial fibrosis and tubular atrophy of >25% in the initial biopsy 
picture is a definite risk factor for progression to renal impairment. 
Patients with   nephrotic proteinuria and those who do not remit have 
higher chance for progression to chronic kidney disease.  
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                                  PROFORMA  
Name:     Age:       Sex:       MRD:       NC No: Date: 
Phone No:    Native:   Wt:  Ht:      BMI: 
Presenting compliance YES/NO Duration 
Edema   
Oliguria   
Frothy urine    
Hematuria   
Diabetes mellitus   
Hypertension   
Joint pain , skin rashes ,oral ulcers,   
Jaundice , Blood transfusion   
Weight loss, treatment for malignancy   
Native drugs , analgesic drug intake   
 
Examination:    Blood pressure:                   Pulse rate: 
      
 C.V.S.:       R.S:        P/A:        C.N.S: 
 
Biopsy report: 
     
Variable Nil 1+ 2+ 3+ 
Interstitial fibrosis &  tubular atrophy     
C1q staining     
 
Follow up:  Y / N                                    Duration of follow up: 
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Laboratory parameters: 
                                                                
Parameters At 
presentation 
3 months 6 months Last follow up 
Urine Protein     
24 h urine pr / uPCR      
Urine RBC     
Hemoglobin     
Sr. Urea     
Sr. Creatinine     
eGFR     
Sr. Total protein     
Sr. Albumin     
Sr. Cholesterol     
Antinuclear antibody   Treatment Drugs Duration 
Hepatitis B surface antigen  Immunosuppressant  
drugs 
  
 Anti hepatitis C antibody  Supportive treatment   
H.I.V  
Stool for occult blood  
Upper G.I. Endoscope  
X ray chest  
C.T. thorax  
Mammography  
Prostate specific antibody  
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CONSENT FORM  
 TITLE OF PROJECT:  
CLINICAL PROFILE, CLINICOPATHOLOGICAL CORRELATION & OUTCOME OF ADULT 
MEMBRANOUS NEPHROPATHY 
Name of Researcher: Dr.ABEESH. P                                    
                                   Please tick to confirm  
  
I confirm that I have read and understand the information provided to me for 
the above study.  
• 
 
I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily.  
• 
  
I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected.  
• 
  I agree to take part in the above research study.  • 
 
__________________________ 
Name of Patient  
______________ 
Date 
__________________________ 
Signature 
 
_________________________ 
Name of Person taking consent  
(if different from researcher) 
_____________ 
Date 
__________________________ 
Signature 
 
Researcher _________ 
 
______________ 
Date 
__________________________ 
Signature 
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PRIMARY MN 
S.NO NAME AGE sex WT EDEMA DM HT RBC uPCR I u PCR >3.5 HB CR I e GFR T.PROTEIN ALBUMINT.CHOLESTROLEBL.SUGAR ANA C3 C4 ANTI ds DNAMOTION OCCULT BL
1 ALBERT 34 M 45 N N N N 2.3 N 13.8 0.9 73.6 5.9 3.1 186 98 NA NA NA NA N
2 BHUVANESWARI41 F 43 N N N N 2.4 N 13.2 1 59.1 5 3 189 95 N NA NA NA N
3 GEETHA 40 M 66 Y N Y N 2.4 N 9 1.9 48.2 5.9 4.1 200 128 N N N N N
4 MALAR 45 F 39 N N N N 3.16 N 14 0.9 59.2 4.9 3.8 168 98 N N N N N
5 MALLIGA 44 F 55 Y N N N 2.7 N 14.8 0.9 69.3 5.6 3.2 172 110 N NA NA NA N
6 MURUGANANTHAM40 M 65 Y N N Y 3.7 Y 13.5 2.1 43 5.7 3.5 170 110 NA NA NA NA N
7 NAGARAJ 56 M 54 Y N Y N 3.1 N 11.8 1.3 48.5 6.6 3.8 196 64 N NA NA NA N
8 NOORLAM 36 M 39 N N N N 3.2 N 10.9 0.8 106.5 6.2 3 210 98 NA NA NA NA N
9 PUSHPA 32 F 56 Y N N Y 2.9 N 10.8 0.8 89.3 6.4 3.2 169 90 NA NA NA NA N
10 RAMALINGAM 43 M 53 Y N N N 1.65 N 13.9 0.8 93 5.7 3.3 210 96 N NA NA NA N
11 SAMPATH KUMAR30 M 66 N N N Y 3.1 N 15.4 1.2 72 3.7 2.8 180 95 N NA NA NA N
12 SATHYA 30 F 58 N N N N 3.8 Y 13 0.9 83.3 5.6 3.9 187 130 N N N N N
13 SELVAN 49 M 51 N N N N 2.96 N 14.8 1.1 58.6 6 4 145 90 N NA NA NA N
14 SENTHIL.B 32 M 71 Y N N N 4 Y 13.8 1 106 6.2 4 234 86 N NA NA NA N
15 SURENDRAN 51 M 77 Y Y N N 3.1 N 12.6 0.9 105 4.8 2.9 198 180 N N N N N
16 SURESH G 27 M 53 Y N N N 8 Y 11.2 1.5 55.5 4.2 4.2 198 88 N N N N N
17 THILLAIRANI 47 F 65 Y N Y N 3.85 Y 8.9 1 61 6 3.2 120 96 NA NA NA NA N
18 ALAGARSAMY 33 M 59 Y N N N 6.4 Y 12 0.9 97.4 5.9 2.1 252 96 N NA NA NA N
19 BABU 37 M 44 Y N N N 6.7 Y 9 1.1 57.2 5.6 2.2 225 110 N N N N N
20 DESAPPAN 53 M 55 Y N Y N 6.3 Y 10.4 1.2 55.4 6.3 2 201 90 N NA NA NA N
21 DEVASIGAMANI52 M 65 N N N Y 4.3 Y 5.2 4.5 66.2 6.7 1.9 220 64 NA NA NA NA N
22 DEVI 31 F 56 Y N N N 5.9 Y 10.8 0.8 90.1 4.8 2.3 228 120 N N N NA N
23 DHANALAKSHMI33 F 43 N N N N 4.5 Y 12.8 1.1 49.4 5.8 2.1 210 180 N N N N N
24 ELANGOVAN.B 52 M 65 Y N N N 3.52 Y 13.8 0.9 75 6 1.8 240 142 NA NA NA NA N
25 GUNASEKARAN41 M 73 Y N Y N 5.1 Y 10.2 1.4 71.7 6.9 3.2 210 120 N N N N N
26 INDRA 47 F 45 Y N N N 7.4 Y 9.2 0.9 68.9 5.6 3.1 290 110 N N N N N
27 JEEVARATHNAM30 M 39 Y N N N 6.6 Y 13.8 0.8 63.3 5.9 2.8 218 94 NA NA NA NA N
28 JEYAKUMAR 40 M 49 Y N N N 8.2 Y 12.1 1.2 56.7 3.8 2.4 330 130 N N N N N
29 JOSEPH 50 M 55 Y N N N 4.1 Y 15.4 1 68.8 6.7 2.6 210 90 NA NA NA NA N
30 KASTHURI 42 F 67 Y N N N 7.4 Y 10.8 0.7 101.3 5.6 2.2 370 90 N NA NA NA N
31 KUPPUSAMY 38 M 69 N N N N 5.13 Y 12.8 1 83.3 5.9 3 198 110 N NA NA NA N
32 MAHALINGAM 52 M 45 Y N N N 5.06 Y 12 0.9 61.1 6.5 3.2 223 96 N N N N N
33 MURUGAN 45 M 76 Y N N N 5.14 Y 14.8 0.9 94.7 5.6 3.1 225 110 N N N N N
34 PACHAIAMMAL44 F 81 Y N N N 6.2 Y 12 0.9 120 4.8 3.2 268 110 N N N N N
35 PARTHIBAN 28 M 70 N N N N 5.7 Y 9.2 0.9 121 5.8 3.5 235 120 N N N N N
36 PARVEEN 30 F 68 Y N N N 5.9 Y 12.8 0.9 98.1 5.8 3.1 190 110 N N N N N
37 POONGODI 44 F 44 Y N Y N 4.5 Y 12.8 0.9 55.4 7 2 220 94 N N N NA N
38 PUSHPARAJ 54 M 65 Y N N N 4.16 Y 13.2 1.3 59.7 4.8 3.2 418 98 N N N N N
39 RAGHU 31 M 66 Y N N Y 6.4 Y 13.8 1.2 83.3 5.8 3.4 260 88 N N N N N
40 RAJESH KUMAR22 M 72 Y N N Y 5.1 Y 12.8 0.9 131.1 5.9 3.7 310 90 N N N N N
41 RASHIDA 63 F 45 Y N N N 5.78 Y 11.8 1.1 53.7 4.8 2.8 280 120 N N N N N
42 SABEENA 23 F 67 Y N N N 5.8 Y 11.4 1.4 66.1 7.5 2.7 138 84 N NA NA NA N
43 SANGEETHA 24 F 67 Y N N N 6.25 Y 11.8 0.9 101.9 6.2 3.4 289 95 N N N N N
44 SEENI 62 M 59 Y N N N 3.16 N 15 0.8 79.9 4 1.8 110 98 N N N N N
45 SEKAR 48 M 60 Y N N N 2.3 N 11 0.9 85.2 5.3 2.9 281 120 N N N N N
46 SIVADASAN 54 M 64 Y N N Y 5.1 Y 12.1 0.9 84.9 4.8 2.5 280 180 NA NA NA NA N
47 SUBRAMANI 56 M 69 Y N N N 5.7 Y 0.8 0.9 89.4 6.8 3 214 95 N N N NA N
48 SURESH.C 25 M 54 N N N N 4.9 Y 10.8 0.85 101.5 5.9 3.2 213 95 N NA NA NA N
FINAL MASTER CHART
49 VARADHARAJAN54 M 67 N N Y N 4.1 Y 12 0.8 100 6.1 2.1 208 140 N N N NEG N
50 VIJAYA 40 F 68 N N N N 3.6 Y 11.3 1 94.4 5 3.2 206 125 N N N N N
51 VISALATCHI 30 F 66 Y N N N 5.8 Y 14 0.9 112 5.5 3.8 216 98 N N N NA N
52 RAMALINGAM 48 M 46 Y N N N 4.6 Y 11 0.9 65.3 5.6 3.2 204 112 N N N NA N
53 MANOHAR 36 M 57 Y N N N 4.3 Y 10 1.1 74.3 5.5 3.4 210 102 N N N NA N
54 RAVI 45 M 49 Y N N N 5.8 Y 11.3 1.2 53.9 5.8 3.5 180 98 N N N NA N
55 SHEELA 38 F 71 Y N N N 6.3 Y 11 1 100.6 6.2 3.2 480 97 N N N NA N
56 REHMAN 47 M 55 N N N N 4.8 Y 12 1.2 59.2 6.7 2.6 170 89 N N N N N
SECONDARY
S.NO NAME AGE sex WEIGHT EDEMA DM HT RBC uPCR I uPCR >3.5 HB CR I e GFR T.PROTEIN ALBUMINT.CHOLESTROLEBL.SUGAR ANA C3 C4 ANTI ds DNAMOTION OCCULT BL
57 ANAPOORANI 28 F 40 N Y N N 3.9 Y 13 1.2 66.5 5.6 3 260 110 N NA NA NA N
58 ANJALI 23 F 36 N N N Y 2.1 N 13 0.8 83.6 6.5 3 231 98 N NA NA NA N
59 BARANI 37 F 55 N N N N 5 Y 13.8 1.5 46.4 6.4 3.5 180 80 NA NA NA NA N
60 BARATHY 37 F 54 N N Y N 3.9 Y 12.3 1 60.7 6.5 3.6 240 89 N N N NA N
61 DEVI 22 F 46 N N N N 2.3 N 9.2 1 80.1 5.9 3.5 150 140 POS L L POS N
62 KALAVATHY 38 F 56 Y N N N 6 Y 13.7 1.3 62.9 6.4 3.4 212 98 N NA NA N N
63 KAMALAVENI 32 F 57 N Y Y N 4.3 Y 8.7 1.6 42.3 6.5 3.5 128 78 POS L L NA N
64 KUMUTHA 23 F 58 N N N Y 3.8 Y 9 1.3 55 6 4 210 89 POS NA NA NA N
65 LAKSHMI 48 F 61 Y N N N 3.8 Y 9.5 1.2 57.6 5.9 3.2 220 112 NA NA NA NA N
66 PADMA 35 F 58 N N Y N 3.06 N 7.7 0.7 85.4 6.1 3.6 290 180 POS N N NA N
67 RAJESWARI 30 F 46 Y N Y Y 4.2 Y 11.5 1.2 76.5 5.5 2.9 280 98 POS NA NA NA N
68 SELVARANI 33 F 51 N N N N 2.7 N 12.6 1.1 65.4 5.8 3.2 190 110 NEG N N N N
69 SELVI 47 F 60 Y N N Y 4.5 Y 11.8 0.8 77.9 6.8 3.2 140 92 NA NA NA NA N
70 SHANTHI 40 F 56 N N N N 2.07 N 10.8 0.9 55.3 6 3.3 190 108 N NA NA NA N
71 TAMIL SELVI 30 F 48 N N Y N 3.7 Y 12.6 0.9 66.9 4.5 3.2 180 140 POS N N N N
72 TAMILSELVI 28 F 49 N N N Y 2.1 N 8.5 1 65.7 6 4.8 120 98 N L L NA N
73 THILAGAVATHY38 F 50 Y N N N 4.2 Y 7.5 1.6 45.1 4.8 4 160 110 POS N N N N
74 UMASELVI 37 F 59 Y N N Y 4.6 Y 15.8 1 52.1 6.5 3.2 115 220 NEG NA NA NA N
75 VANI 39 F 60 Y N N Y 4.7 Y 16.2 1 66.3 5.4 4.9 120 64 NA NA NA NA POS
76 RAJESWARI 50 F 55 Y N Y N 4.2 Y 11.2 0.8 130.7 5.6 3.2 179 120 N NA NA NA N
77 NATHYA 25 F 52 N N N Y 2.2 N 5.8 1.8 47.2 5.4 2.8 254 76 NA NA NA NA N
78 SATHYA 35 F 49 N N N Y 3.2 N 12 0.9 73.2 4.9 3.5 236 100 POS N N N N
79 SASIKALA 35 F 50 N N N N 2.5 N 8.2 1 66.3 5.8 3.8 121 120 N N N N N
80 BALARAMAN 69 M 62 Y N N N 3.2 N 10.5 0.9 73.5 5.4 3.8 215 98 NA NA NA NA N
81 GOWTHAM KUMAR24 M 67 Y N N Y 3.4 N 13 1.6 40.5 5.8 3.2 190 94 POS NA NA POS N
82 KANNAN 39 M 72 Y N N Y 3.75 Y 12 1.1 65.2 5.6 3.7 140 98 POS NA NA NA N
83 KARTHIK 25 M 77 N N N Y 4.1 Y 10.2 1.2 43.3 4.5 3.2 192 120 POS L L NA N
84 KUMAR 41 M 65 N N N Y 4 Y 12.5 0.8 77.5 6.8 4.1 128 110 N NA NA NA N
85 MARIO 33 M 66 Y N N N 2.1 N 10.8 0.9 71.2 5.7 4 136 98 POS NA NA NA N
86 PRAKASH 35 M 76 Y N N N 4.6 Y 12 0.8 76.1 6.3 3.6 173 96 NEG NA NA NA N
87 SURESH P 34 M 61 Y N N N 3.85 Y 11.8 0.9 78.4 5.5 3 205 95 N N N NA N
88 THIRUPATHY 30 M 48 Y N N N 2.1 N 10.3 1.1 61.3 5.6 3.7 185 98 POS L L NA N
89 ALPHONES 64 M 58 Y Y N Y 4.3 Y 13.8 0.8 117.8 4.2 3 213 120 N N N N N
90 BHESEER 54 M 60 Y N Y N 4.2 Y 13.8 0.9 84.4 5.2 3.9 180 89 POS N N NA N
91 MOHAN 36 M 54 Y N N N 4.4 Y 13.8 0.9 84.8 6 3.3 160 110 POS NA NA NA N
92 PONNAN 57 M 71 N N N Y 3.1 N 12.3 0.5 128.3 6.3 3 160 98 NEG N N N N
93 KANNAN 50 M 77 N N N N 3.3 N 12.9 0.7 89 6.1 3.5 125 110 POS N N N N
HBSAG ANTIHCV HIV PSA CT THORAX OGDMAMMOGRAPHYAPLA2R IFTA IGG IGM IGA C3c C1Q ACEI/ARB M. P REMISION CR II e GFR uPCR II ALBUMIN II
N N N N NIL NIL POS 1 2+ 1+ 1+ 2+ 0 Y Y Y 1 0.9 73.6 2.9 3.9
N N N NIL NIL N NA 1 2+ 1+ 0 1+ 0 Y N Y 1 0.9 61 1.6 4.2
N N N N NIL NIL NA 0 2+ 0 0 2+ 0 Y Y Y 1 1.2 64 1.3 4.3
N N N N NIL NIL N NA 0 4+ 0 2+ 2+ 0 Y N Y 1 0.9 59.2 1.4 3.9
N N N NIL NIL N NEG 1 4+ 3+ 0 2+ 0 Y Y Y 1 0.8 72.3 1.3 4.8
N N N NIL NIL NA 0 2+ 2+ 0 2+ 0 Y Y Y 0.9 85.3 1.6 4.1
N N N N NIL NIL POS 0 3+ 0 0 2+ 0 Y Y Y 1 1.1 54.2 2.2 3.9
N N N NIL NIL POS 0 3+ 0 0 1+ 0 Y N Y 1 1.1 90.6 1.2 3.1
N N N NA NA NA NA 0 4+ 0 2+ 3+ 0 Y N Y 1 5.8 13.8 0.23 3
N N N N NIL NIL NA 2 4+ 1+ 0 1+ 0 Y N Y 1 0.8 75.9 2.6 4.6
N N N NIL NIL POS 0 2+ 0 0 1+ 0 Y N Y 1 1 84.6 2.4 3.4
N N N NIL NIL N NA 1 4+ 2+ 0 3+ 0 Y N Y 2 0.9 83.3 1.5 4
N N N NIL NIL NA 0 4+ 0 0 3+ 0 Y Y Y 1 1 62.7 1.1 4.6
N N N NA NIL NIL POS 1 3+ 0 0 1+ 0 Y Y Y 1 1.1 78.2 3.2 3.9
N N N N NIL NIL NA 0 4+ 0 0 3+ 0 Y N Y 1 1 72.6 1.3 4
N N N N NIL NIL POS 0 3+ 0 0 0 1+ Y Y Y 1 1.4 59.4 3.6 3.2
N N N NIL NIL POS 2 2+ 0 0 0 0 Y N Y 2 1.2 59.5 1.8 3.9
N N N N NIL NIL POS 0 3+ 1+ 0 3+ 0 Y Y N 1 1.1 67.8 5.3 4
N N N N NIL NIL POS 0 3+ 3+ 3+ 3+ 0 Y Y N 1 1.2 56 4.2 3.1
N N N N NIL NIL POS 0 3+ 0 0 3+ 0 Y Y N 1 1.2 55.4 4.8 3.2
N N N NA NA NA NA 1 3+ 0 0 3+ 0 Y N N 1 4.5 66.2 3.4 4
N N N NIL NIL N POS 0 3+ 0 0 3+ 0 Y Y N 1 1.3 74 4.8 3.4
N N N NIL NIL N NA 3 2+ 0 0 2+ 0 Y N N 1 0.8 62 4.3 3
N N N NA NIL NIL POS 1 4+ 0 0 3+ 0 Y Y N 1 1.1 68 4.7 4.1
N N N N NIL NIL NA 0 3+ 0 0 3+ 0 Y Y N 1 1.4 71.7 5.1 3.4
N N N NIL NIL N POS 1 3+ 1+ 0 1+ 0 Y Y N 1 0.9 68.9 3.5 3.5
N N N NA NA NA NA 0 4+ 0 0 2+ 0 Y Y N 1 1 60 2.8 3.1
N N N N NIL NIL NA 3 3+ 2+ 0 2+ 0 Y Y N 1 7.4 7.9 7.1 3.6
N N N N NIL NA POS 0 3+ 0 0 1+ 0 Y Y N 1 1.2 64 3.7 3.1
N N N NIL NIL N POS 1 4+ 2+ 0 3+ 0 Y Y N 1 0.9 98.2 4.5 3.2
N N N NIL NIL NA 1 4+ 2+ 0 3+ 0 Y N N ?1 0.8 94 5.2 3.1
N N N NA NIL NIL NA 1 2+ 0 0 0 1+ Y N N 1 0.9 61.1 4.2 3.1
N N N NIL NIL POS 0 3+ 0 0 2+ 0 Y Y N 1 0.9 94.7 7.2 3.9
N N N NIL NIL N NEG 0 3+ 0 0 0 1+ Y Y N 2 0.9 120 3.6 3.4
N N N NIL NIL NEG 3 4+ 0 0 4+ 0 Y N N 4.6 20.1 8.2 3.2
N N N NIL NIL N NEG 0 2+ 2+ 0 0 0 Y N N 1 1 96.2 6 4
N N N NIL NIL NEG 0 3+ 0 0 3+ 0 Y Y N 2 1.4 35.6 4.6 3.1
N N N N NIL NIL NA 3 2+ 0 0 0 1+ Y N N 1 3.6 18.3 2.3 3.1
N N N NIL NIL NEG 1 4+ 2+ 0 2+ 0 Y Y N 1 1.1 89.2 4.6 4
N N N NIL NIL NA 0 4+ 1+ 0 4+ 0 Y Y N 1 0.9 131.1 4.3 3
N N N NIL NIL N NEG 0 2+ 2+ 0 0 0 Y N N 2 1.2 50.8 4.8 3.1
N N N NIL N NEG 0 2+ 0 0 0 0 Y N N 1 1.1 78.2 4.9 2.9
N N N NIL NIL N POS 0 3+ 0 0 1+ 0 Y N N 1 1 96.2 3.9 3.1
N N N N NIL NIL POS 0 4+ 0 0 4+ 0 Y Y N 1 1.5 36.2 4.4 3.1
N N N N NIL NIL NEG 0 3+ 0 0 2+ 0 Y Y N 1 1.2 72.2 4.5 3.2
N N N NA NA NA NA 3 3+ 1+ 0 2+ 0 Y N N 2 4.3 15.1 6.1 3
N N N N NIL NIL NEG 0 3+ 0 0 3+ 0 Y N N 1 1.3 68.2 4.8 3.1
N N N NIL NIL NA 0 4+ 1+ 1+ 4+ 0 Y Y N 1 1.5 52.6 4.5 3.1
FINAL MASTER CHART
N N N NIL NIL NA 0 4+ 1+ 0 1+ 0 Y Y N 1 1.1 88.2 8.7 3
N N N NIL NIL N POS 1 4+ 2+ 0 0 0 Y Y N 1 1.3 78.7 4.18 3.3
N N N NIL NIL NA NEG 1 N 0 0 0 0 Y Y N 2 0.9 112 4.8 3.4
N N N NIL NIL NEG 1 N 0 0 0 0 Y Y N 2 1 65.3 4.6 3.4
N N N NIL NIL NEG 1 2+ 1+ 3+ 1+ 0 Y Y N 1.2 70.8 4.6 3.9
N N N N NIL NIL NEG 0 2+ 1+ 0 1+ 0 Y N N 1 60.7 3.8 3.1
N N N NIL NIL N NEG 0 2+ 0 0 1+ 0 Y N N 1 100.6 3.8 3.8
N N N N NIL NIL NEG 0 2+ 0 0 1+ 0 Y Y N 1 60.8 3.6 3.1
HBSAG ANTIHCV HIV PSA CT THORAX OGDMAMMOGRAPHYAPLA2R IFTA IGG IGM IGA C3c C1Q ACEI/ARB M. P REMISION CR II e GFR uPCR II ALBUMIN II
N N N NA NA NA NA 0 4+ 0 0 4+ 0 Y N N 1 0.8 NOT DONE 2.7 3.1
N N N NIL NIL N NA 0 4+ 4+ 1+ 2+ 2+ Y N N 2 1.4 NOT DONE 3.6 3.1
POS N N NIL NIL NEG 0 3+ 0 0 3+ 0 Y N N 2 1.9 NOT DONE 6.9 3
N N N NIL NIL N NA 0 3+ 0 0 0 0 Y N Y PARTIAL 0.8 NOT DONE 3.85 3.1
N N N NIL NIL N NEG 1 4+ 2+ 2+ 4+ 3+ Y N N 2 1.2 NOT DONE 3.2 3.9
N N N N NIL NIL NEG 1 3+ 0 0 3+ 3+ Y N Y 2 1.1 NOT DONE 2.5 3.9
N N N NIL NIL NEG 1 3+ 2+ 2+ 3+ 1+ Y N Y 2 1.1 NOT DONE 4.3 3.1
N N N NIL NIL NIL NEG 1 3+ 1+ 3+ 0 3+ Y N N 0.8 NOT DONE 1.2 3.9
N N N NIL NIL N NA 1 2+ 0 0 0 0 Y N N 2 1 NOT DONE 3.4 3.7
N N N NIL NIL N NA 0 4+ 3+ 1+ 0 0 Y N Y 2 1 NOT DONE 2.8 3.1
N N N NIL NIL NEG 1 4+ 2+ 2+ 2+ 2+ Y N N 2 0.9 NOT DONE 0.9 3.7
N N N NIL NIL N NEG 0 4+ 0 0 2+ 0 Y N Y 2 1.8 NOT DONE 1.2 3.4
N N N NIL NIL NA 1 4+ 1+ 2+ 3+ 1+ Y N N ?1 2.3 NOT DONE 1.8 3.4
N N N NIL NIL N NEG 0 4+ 2+ 0 4+ 0 Y N Y 1 1.4 NOT DONE 2.5 3.4
N N N NIL NIL N NEG 1 4+ 2+ 0 4+ 0 Y N Y 1 1.2 NOT DONE 4.8 3.1
N N N NIL NIL NA 1 4+ 3+ 2+ 3+ 2+ Y N N 2 0.9 NOT DONE 5.2 4.1
N N N N NIL NIL NA 1 4+ 2+ 2+ 3+ 0 Y N Y 1 5.8 NOT DONE 4.9 3.1
N N N 0.35 ng/ml (4.1)NIL ANTRAL NODULE NEG 0 3+ 0 0 0 3+ Y N N 2 0.9 NOT DONE 3.8 4
N N N NA NIL NIL NEG 0 2+ 0 0 0 0 Y N Y PARTIAL 2 0.8 NOT DONE 3.17 4.6
N N N NIL N NA 2 4+ 3+ 0 4+ 2+ Y N Y 2 0.9 NOT DONE 5.6 3.5
N N N NIL NA NA 3 3+ 0 3+ 3+ 3+ Y N N 2 2.6 NOT DONE 3.5 3.1
N N N NIL NIL N NEG 1 2+ 0 0 0 0 Y N N 2 0.6 NOT DONE 2.9 3.9
N N N NIL NIL N NA 0 2+ 2+ 1+ 2+ 0 Y N Y 2 4.6 NOT DONE 5.2 3.1
N N N NIL NIL NA 0 4+ 2+ 3+ 3+ 3+ Y N Y 2 0.8 NOT DONE 0.5 4
N N N NIL NIL NEG 0 3+ 0 1+ 2+ 1+ Y N Y PARTIAL 2 1.8 NOT DONE 2.66 2.9
N N N NIL NIL NIL NEG 1 4+ 1+ 3+ 4+ 3+ Y N N 2 0.8 NOT DONE 2.1 4.5
N N N NIL NIL NA 0 3+ 2+ 0 3+ 2+ Y N N 1 0.9 NOT DONE 3.6 3.6
POS N N NIL NIL N NA 2 2+ 0 0 2+ 0 Y N N 2 0.8 NOT DONE 4.5 4.1
N N N NIL NIL N NA 1 4+ 4+ 2+ 2+ 2+ Y N Y 2 9.6 NOT DONE 9 4.1
N N N NIL ANTRAL NODULE NEG 1 2+ 0 0 2+ 0 Y N N 2 0.9 NOT DONE 4.1 4.1
N N N NIL NIL N NEG 3 3+ 0 0 3+ 0 Y N Y PARTIAL 2 0.8 NOT DONE 0.33 3.5
N N N NIL NIL NA 1 3+ 0 2+ 3+ 2+ Y N N 2 1.3 NOT DONE 3.5 4.2
N N N N NIL NIL NA 0 2+ 1+ 1+ 2+ 1+ Y N N 2 1.4 NOT DONE 5.2 3.2
N N N NIL NIL NA 0 4+ 3+ 0 2+ 2+ Y N N 2 1 NOT DONE 3.4 3.3
N N N N NIL NIL NA 3 4+ 2+ 2+ 4+ 3+ Y N N 2 1.6 NOT DONE 3.7 3.2
N N N NIL NIL NA NEG 1 2+ 0 0 2+ 2+ Y N Y 2 0.9 NOT DONE 5.1 3.1
N N N NIL NIL N NA 0 4+ 3+ 2+ 2+ 0 Y N N 2 0.9 NOT DONE 0.4 3
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 ìì° SÉœ—mkÇÂ −zx¶ B©·Ô ·¶ª[PÇ GÏUS 
·ÂUPœ–mhx. GÔÒíh¤  \•ìuP[PíÂ ìPmP¹£, AuÍPêÏ uS•u 
·ÂUP[PíÂœ ë–È¹£ ¶ê©œ–ÃUPœ–mhx. 
 
 {êÔ C»B©·µ uÔÐaí\¤êPzuêÔ –[ìPÍQìÈÔ. G•uU 
PêªnzvÏêì°ê G•uU Pmhzv³£ G•u \mh ]UP³US£ Em–hêµ 
{êÔ C»B©·µ C−•x ·°QU ëPêÇÂ°ê£ GÔË£ AÉ•x ëPêsìhÔ. 
 
 C•u B©¹ \£•uêPì¶ê, Cíu \ê¯•u ì³£ B©¹ 
ìÍëPêÇÅ£ì–êx£ C•u B©·µ –[Së–Ë£ −zx¶¯ GÔÒíh¤ 
−zx¶ AÉUíPPíÂœ –ê¯œ–uÍS GÔ AÒv ìuí¶¥µí° GÏ 
AÉ•x ëPêÇQìÈÔ. {êÔ B©·µ C−•x ·°QU ëPêshê³£ Cx 
ë–ê−•x£ GÏ AÉQìÈÔ. 
 
 C•u B©·Ô ¢°£ QíhUS£ uP¶µPíÂ§£, –«ì\êuíÏ 
¡i¹PíÂ§£ ÍË£ ]Qaí\ ëuêh¯–êÏ uP¶µPíÂ§£ −zx¶¯ 
ìÍëPêÇÅ£ B©·µ –¤Ô–kzvU ëPêÇÂ¹£ Aíuœ —ª_«UP¹£ GÔ 
¡¿ ÏxhÔ \£vUQìÈÔ. 
 
 C•u B©·µ –[S ëPêÇÂ Jœ™UëPêÇQìÈÔ. GÏUSU 
ëPêkUPœ–mh AÉ¹íªPÃÔ–i {h•x ëPêÇ¶xhÔ, C•u B©í¶ 
ìÍëPêÇÅ£ −zx¶ AoUS Esí§hÔ C−œì–Ô GÔË£ 
EËv¤ÃUQìÈÔ. GÔ Ehµ {°£ –êvUPœ–mhêì°ê Aµ°êu Gv¯–êªêu 
¶¼UPzvÍS ì{ê©USÉ ëuÔ–mhêì°ê EhìÏ Aíu −zx¶ Ao¥h£ 
ëu«·œì–Ô GÏ EËv AÃUQìÈÔ. 
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£ìªÏá ë{œìªê–v GÔÒ£ ]Ë}ªP ì{êí¤ PshÉ•x AuÔ 
uÔíí¤ Bªê©¶ìu C•u B©·Ô ì{êUPêS£. 
 
 C•u Bªê©a]¥Ô ¡i¹PíÂ Aµ°x P−zxUPíÂ ë¶Ã¥k£ ì–êìuê 
Aµ°x Bªê©a]¥Ô ì–êìuê u[PÂx ë–¤íªì¤ê Aµ°x Aíh¤êÂ[PíÂì¤ê 
ë¶Ã¥h êmìhê£ GÔ–íu§£ ëu«·zxUëPêÇQìÈê£. 
 
 C•u Bªê©a]¥µ –[ìPÍ–x u[PÅíh¤ ·−œ–zvÔ ì–«µ uêÔ 
C−UQÈx. ì³£ }[PÇ G•ì{ª¡£ C•u Bªê©a]¥±−•x —Ô¶ê[P°ê£ 
GÔ–íu§£ ëu«·zxUëPêÇÂ°ê£. 
 
 C•u ]Èœ™œ –«ì\êuíÏPÃÔ ¡i¹PíÂ Bªê©a]¥Ô ì–êx Aµ°x 
Bªê©a]¥Ô ¡i·Ô ì–êx u[PÅUS AÉ·œì–ê£ GÔ–íu§£ 
ëu«·zxUëPêÇQìÈê£. 
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